Loading
REC-4881 is an experimental small molecule, allosteric MEK1/2 inhibitor from Recursion Pharmaceuticals, in phase 2 trials for familial adenomatous polyposis.
REC-4881 is a small molecule, allosteric MEK1/2 inhibitor (oral) from Recursion Pharmaceuticals. An orally bioavailable, non-ATP-competitive, allosteric inhibitor of MEK1 and MEK2, developed to reduce polyp burden and progression to adenocarcinoma in familial adenomatous polyposis. Its furthest stage is phase 2, for familial adenomatous polyposis (cancer predisposition; prevention of colorectal and upper GI adenocarcinoma). ClinicalTrials.gov registers it in 2 studies linked below. Pipeline page: 'Status: Phase 2', Fast Track and US/EU Orphan Drug. Registry: NCT05552755 (TUPELO, phase 1/2, FAP) recruiting; NCT06005974 (AXIN1/APC-mutant solid tumours, phase 2) terminated. Whether it works in people has not been established unless a trial below reports it.
An orally bioavailable, non-ATP-competitive, allosteric inhibitor of MEK1 and MEK2, developed to reduce polyp burden and progression to adenocarcinoma in familial adenomatous polyposis. Connects to MEK1/2.
1.REC-4881 slips into a pocket on MEK1/2.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"REC-4881" OR ABSTRACT:"REC-4881") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about REC-4881, not a curated reading list.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares MEK1/2 and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/